Compare SVRE & GCTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SVRE | GCTK |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5M | 1.6M |
| IPO Year | N/A | 2011 |
| Metric | SVRE | GCTK |
|---|---|---|
| Price | $2.99 | $1.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 120.3K | ★ 205.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17910.53 |
| EPS | N/A | ★ 30.09 |
| Revenue | N/A | ★ $589,462.00 |
| Revenue This Year | $453.30 | N/A |
| Revenue Next Year | $106.57 | N/A |
| P/E Ratio | ★ N/A | $0.05 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $0.09 |
| 52 Week High | $5.69 | $15.90 |
| Indicator | SVRE | GCTK |
|---|---|---|
| Relative Strength Index (RSI) | 83.38 | 25.95 |
| Support Level | $1.99 | $1.52 |
| Resistance Level | $3.11 | $4.24 |
| Average True Range (ATR) | 0.12 | 0.13 |
| MACD | 0.17 | 0.07 |
| Stochastic Oscillator | 96.20 | 24.48 |
Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road and pedestrians. Geographially, it operates in Israel and Europe, out of which it derives maximum revenue from Israel.
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.